ASGR1 and liver cancer: The work of the pharmaceutical technology research group of the University of Bari fits into this context: Iacobazzi et al. [32] reported the development of a fourth generation (G(4)) PAMAM dendrimer encapsulating the anticancer drug sorafenib, which is able to target, thanks to the surface lactobionic acid tag, the asialoglycoprotein receptor (ASGP-R), which is usually overexpressed in human liver cancer cell lines such as HepG2 cells.